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Objective:  To  describe  the  rare  association  between  primary  biliary  cirrhosis  (PBC)  and  Graves  disease
(GD).
Methods:  Report  the  clinical,  biochemical,  and  pathological  ﬁndings  of the  patient  and  review  the  relevant
literature.
Results:  Female,  63 years  old, sent  to the  endocrinologist  for hyperthyroidism.  The patient  had  a  history
of  cholecystectomy  and PBC  diagnosed  9 years  (previously).  Before,  she  reported  palpitations,  excessive
sweating,  irritability  and  weight  loss.
Physical  examination:  heart  rate  of 80 bpm,  coarse  tremor,  bosselated  thyroid  and  non-pulsatile.
Laboratory  ﬁndings:  TSH 0.01  UI/mL  (0.27–4.20),  free  T4  3.76  ng/dL  (0.93–1.7),  anti-TPO  244 UI/mL  (<34),
TRAbs  4.2  U/L  (<1.5).
Patient  was treated  with  methimazole  15  mg/day  and  propranolol  20  mg/day.  For persistence  of hyper-
thyroidism,  despite  the  increase  in  the  methimazole  dose,  the patient  underwent  radioiodine  therapy.
Afterwards  the  developed  hypothyroidism  and therefore  was treated  with  levothyroxine.  She  is currently
euthyroid.
Conclusion:  Despite  frequent  association  of  autoimmune  diseases  in  the same  individual,  the authors
present  this  case  because  of  the  rare association  between  PBC  and  GD.
©  2012  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier
España,  S.L.  All  rights  reserved.
Cirrose  biliar  primária  e  doenc¸ a  de  Graves—Uma  combinac¸ ão  rara
alavras-chave:
oenc¸ a de Graves
irrose biliar primária
r  e  s  u  m  o
Objectivo:  Descrever  a associac¸ ão  rara  entre  cirrose  biliar  primária  (CBP)  e  doenc¸ a de  Graves  (DG).
Métodos: Descrevemos  os  dados  clínicos,  bioquímicos  e  patológicos  do doente  e revemos  a  literatura
relevante.
Resultados:  Sexo feminino,  63  anos,  enviada  à consulta  de  endocrinologia  por  hipertiroidismo.  Paciente
apresentava  antecedentes  de  colecistectomia  e  CBP  diagnosticada  há  9 anos.  Referia  palpitac¸ ões,  sudorese
excessiva,  irritabilidade  e  perda de  peso.
Exame  físico:  frequência  cardíaca  de 80 bpm,  tremor  grosseiro,  tiroide  bosselada  e não  pulsátil.  Dados  lab-
oratoriais:  TSH  0,01  UI/mL (0,27–4,20),  T4  livre  3,76  ng/dL  (0,93–1,7),  anti-TPO  244 UI/mL  (<34),  TRAbs
4,2  U/L  (<1,5).
A paciente  foi  medicada  com  metimazol  15  mg/dia  e propranolol  20 mg/dia.  Por  persistência  do  hiper-
tiroidismo,  apesar  do  aumento  da dose  do  metimazol,  a doente  foi  submetida  a terapêutica  com  iodo.
Posteriormente  desenvolveu  hipotiroidismo  e, por  isso,  foi  medicada  com  levotiroxina.  Atualmente,  está
em eutiroidia.
Conclusões:  Apesar  da  associa
apresentam  este  caso  pela  asso
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Primary biliary cirrhosis (PBC) is most frequently a women’s
isease1 that occurs between the ﬁfth and seventh decades of life.2
he etiology is unknown, although it is presumed to be autoim-
une in nature.1–3 The classic pathophysiological process in PBC is
amage to the biliary epithelial cells lining the small intrahepatic
ile ducts (and their progressive destruction). Bile duct loss is pro-
ressive and in the end stages of the disease there can be a complete
oss of small intrahepatic ducts. Fibrosis occurs within the liver as a
onsequence of progressive damage, and this can lead to cirrhosis
ver a variable time period.4
Associations between PBC and other autoimmune diseases
ave been reported: autoimmune thyroiditis, rheumatoid arthri-
is, Sjögren’s syndrome and Raynaud’s phenomenon.1,3,5 Although
ssociation of PBC with hyperthyroidism is quite rare,3,5–7 in
his case report the authors describe a patient with PBC and
yperthyroidism by Graves’ disease (GD). Only six patients with
BC and hyperthyroidism have been reported in the literature:
our with GD, one with hashitoxicosis and another with painless
hyroiditis.1,3,8–10
ase report
A 55-year-old woman was admitted due to liver dysfunction
n February 1998. Six months earlier, she was found to have an
levated level of -glutamyl transpeptidase (-GTP) at 590 U/L
normal range, 7–32), alkaline phosphatase (ALP) at 570 U/L (nor-
al  range, 36–101), aspartate aminotransferase (AST) at 51 U/L
normal range, 10–42) and alanine aminotransferase (ALT) at 57 U/L
normal range, 10–40); hemogram with platelets and bilirrubin
ere normal; eritrocyte sedimentation rate (ESR) was 63 (normal
ange, <35). This patient was not an alcoholic, and had no history of
lood transfusions or drug allergies but with a history of cholecys-
ectomy for 22 years previously due to gallstones. She had malar
ryhtema; no ascites, edema or xanthomas.
Abdominal ultrasonography: “Liver with increased size, regular
orders and uniform texture; normal biliary duct system, spleen,
ancreas and kidneys without changes.”
Antimitochondrial antibodies (AMAs) were positive (+++). Hep-
titis C virus and hepatitis B surface antigen were both negative.
nti SSA, SSB, Sm,  RNP, Scl70, centromere, nucleolar, gastric pari-
tal cells, liver–kidney microsomal, actin, gliadin, endomisio and
eticulina antibodies, were negative as well. Antinuclear antibody
able 1
aboratorial ﬁndings of the patient.
December 1997 Novemb
Total bilir. (mg/dL) 0.6 1.3↑ 
Direct bilir. (mg/dL) 0.2 0.4↑ 
AST  (U/L) 51↑ 51↑ 
ALT  (U/L) 57↑ 39 
-GT  (U/L) 590↑ 102↑ 
ALP  (U/L) 570↑ 239↑ 
able 2
hyroid status and medication.
17/11/06 20/12
TSH (UI/mL) 0.01↓ 0.01↓
FT4  (ng/dL) 3.76↑ 2.65↑
Anti-TPO (UI/mL) 244↑
Anti-TG (UI/mL) 58.2 
TRABs (U/L) 
Methimazole doses 15 m
Propranolol doses 20 mabetes Metab. 2013;8(2):97–99
(ANAs) and anti smooth muscle antibody (SMA) were positive
(+++).
Pathological study of the biopsy material from the liver showed
PBC stage IV (“. . .septal ﬁbrosis, sometimes delimited nodules of
hepatocytes. . . portal spaces are expanded by the presence of a
mononuclear inﬁltrate of moderate intensity, accompanied by duc-
tular reaction and paucity of bile and interlobular ducts. There is
halo effect where the periportal hepatocytes have clear cytoplasm
and xanthomatous appearance of protein deposits associated with
copper, indicating chronic cholestasis. Periportal inﬂammatory
activity of type bile and mild lobular, as well as bilirrubinosta-
sis”). The patient was diagnosed as PBC due to the clinical criteria
and pathological ﬁndings. Treatment with ursodeoxycholic acid
750 mg/day was  initiated.
The patient was  followed in the Gastroenterology department
and treated with immunosuppressors and immunomodulators.
Only one hospitalization, in April 2006, for decompensation (jaun-
dice and bilirubinuria) (Table 1).
In December 2006 the patient was sent to the Endocrinology
outpatient clinic for hyperthyroidism. At the time, she was being
treated with ursodeoxycholic acid 500 mg  twice a day. Palpitations,
excessive sweating, irritability and weight loss were reported in the
previous month.
Physical examination revealed blood pressure of 130/80 mmHg
and pulse was 80 beats/min; no exophthalmia. She presented
coarse tremor, bosselated and non-pulsatile thyroid. Labora-
tory ﬁndings: TSH 0.01 UI/mL (0.27–4.20), free T4 3.76 ng/dL
(0.93–1.7), anti-TPO 244 UI/mL (<34) and TRAbs 4.2 U/L (<1.5)
(Table 2).
She was then treated with methimazole 15 mg/day and propra-
nolol 10 mg  twice a day.
Thyroid ultrasonography showed an enlarged, lobulated,
slightly heterogeneous gland and a nodule with 1 cm in diameter
in the left lobe (Fig. 1).
Fine-needle aspiration biopsy was performed and the diagnosis
was colloid nodule.
The iodine thyroid scintigraphy showed diffusely increased
uptake and distributed
almost uniformly with only a small hypoactive area located on
the middle third of the left lobe; this study was  highly suggestive
of Graves’ disease.The methimazole dose was  carefully increased because of previ-
ous liver disease. Due to persistence of hyperthyroidism and slight
worsening of liver tests, the patient underwent radioiodine therapy
(7.4 mCi).
er 2006 February 2007 Normal range
0.7 0.3–1.0
0.3 <0.3
32 10–42
20 10–40
112↑ 7–32
306↑ 36–101
/06 16/01/07 Normal range
 0.01↓ 0.4–4
 1.8 0.78–1.94
 2806↑ <60
16.5 <60
4.2↑ <1.5
g 20 mg
g 15 mg
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1Fig. 1. Nodule with 1 cm in the left lobe of thyroid.
Afterwards the patient developed hypothyroidism and was
herefore treated with levothyroxine (0.15 mg/day). She is cur-
ently euthyroid.
iscussion and review of literature
PBC is diagnosed by liver biopsy and presence of AMAs. AMAs
an be found in 90–95% of patients with PBC, and have a speciﬁcity
f 98% for this disease. ANAs can be identiﬁed in 20–50% of patients
ith PBC; SMA  may  also be found in this type of patients.11 Lab-
ratory data in our patient fulﬁlled all diagnostic criteria for PBC:
igniﬁcant elevations of the ALP and -GT; elevated ESR is present
n most cases.
It is possible that a patient with one autoimmune disease
resents another one. PBC with hyperthyroidism was reported in
nly six patients: four with GD, one with hashitoxicosis and another
ith painless thyroiditis.
GD is currently accepted as an autoimmune disease of unknown
tiology. The gene CTLA-4 (Cytotoxic T lymphocyte-associated
ntigen-4), located on chromosome 2q33 has been implicated in
he onset of GD and PBC. CTLA-4 is a T cell surface molecule which
nteracts (in competition with the costimulatory molecule CD28)
ith the ligands B7-1 and B7-2 on antigen-presenting cells to
nﬂuence the induction, maintenance and, particularly, termina-
ion of peripheral T cell responses.12–14 The net interaction of CD28
nd CTLA-4 with their ligands may  inﬂuence the nature of T-cell
esponses by determining the extent and kinetics of T cell activa-
ion.
A strong association between the CTLA-4 exon 1 polymorphism
nd PBC was reported.12 Meta-analysis involving over 13,000 sub-
ects found signiﬁcant association between polymorphisms in the
49G and CT60 alleles with GD and Hashimoto’s thyroiditis.15 This
upports the hypothesis that common immunoregulatory path-
ays may  be involved in the etiology of autoimmunity.
Finally, both diseases, GD and PBC, are associated with
RB1*0801.17,18
1
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Conclusion
Like several bizarre autoimmune associations, this case shows
that the connection of PBC with GD is possible (although extremely
rare).
The choice of methimazole and the careful increase of dosage
was due to the following facts: hepatic toxicity with methimazole is
not as severe as the potentially life-threatening hepatocellular reac-
tions that are seen with propylthiouracil; the patient had abnormal
hepatic tests predominantly cholestatic – rare hepatic abnormal-
ities associated with methimazole are typical of a cholestatic
process; the side effects of methimazole are dose-related.16 In cases
of previous liver disease we propose the monitoring of liver tests
due to the possibility of worsening. If necessary, treatment should
be made with 131I (which happened in this case).
Our recommendation for all clinicians is that when a patient
has an autoimmune disease, extra attention should be paid to the
signs and symptoms in order to investigate the presence of another
autoimmune disease as the association of diseases with this etio-
logic basis is common.
Conﬂicts of interest
The authors declare no conﬂicts of interest.
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